Angiogenic gene therapy in patients with cerebral infarcts may have clinical benefit, but its potential is diminished by the difficulty of introducing genes into the brain. We evaluated the safety and efficacy of ultrasound-targeted microbubble destruction (UTMD) for delivery of genes to the brains of normal mice and after transient middle cerebral artery occlusion. In normal mice, disruption of the blood-brain barrier detected with trypan blue staining was reversible within 24 hours of a single UTMD administration. Expression of reporter genes in the brain after UTMD demonstrated successful targeted gene delivery and transfection. Decreased neurologic function after transient middle cerebral artery occlusion was attenuated versus controls at 7 days after UTMD delivery of vascular endothelial growth factor. Ultrasound-targeted microbubble destruction delivery of the VEGF gene resulted in decreased infarct areas, increased vessel density, and reduced apoptosis versus controls. There was no evidence of permanent brain injury throughout the study. Thus, UTMD was a safe, minimally invasive, effective technique for gene delivery to the brain. Vascular endothelial growth factor transfection of brain cells conferred beneficial effects on histopathologic parameters and neurologic function, and stimulated angiogenesis in a mouse stroke model.
INTRODUCTION
Stroke is a devastating complication of cerebral arterial occlusion that is only partially reversed with reperfusion. The most appropriate treatment after a stroke has not been established. New methods of neuroprotection, neural angiogenesis, and neurogenesis are urgently required to reduce the profound mortality and long-term disability associated with stroke (1) . Increased cerebral microvascular circulation in stroke patients has been correlated with better functional recovery after a stroke (2) , and enhancement of this natural course of angiogenesis may partially compensate for strokeassociated tissue hypoperfusion. Treatment with vascular endothelial growth factor (VEGF) has been shown to induce angiogenesis, to stimulate neurogenesis, and to improve functional recovery after stroke (3Y5). A variety of delivery platforms for VEGF have been evaluated, but the ideal method has not been established. Many previous gene therapy studies used invasive gene delivery methods (6Y8), including injecting viral vectors into intracerebral ventricles (3) , which may cause tissue injury. Intravenous delivery of VEGF plasmid is a commonly used technique for increasing angiogenesis in the brain, but the gene has a limited capacity to pass through the blood-brain barrier (BBB). In addition, excess VEGF in the circulation increases vascular permeability and contributes to cerebral edema (9) . Therefore, the beneficial effects of VEGF require an accurate delivery of the optimal dosage at the most appropriate times to the precise peri-infarct brain region after cerebral vascular occlusion. Minimally invasive techniques will permit titration of the appropriate dose and optimization of the timing of VEGF delivery.
Ultrasound-targeted microbubble destruction (UTMD) is a minimally invasive method to effectively deliver therapeutic agents, such as drugs, proteins, and plasmids, to targeted organs. We have previously found that UTMD-mediated gene therapy (including delivery of VEGF gene) targeted at the heart improved myocardial perfusion and cardiac function after myocardial infarction in mice and rats (10, 11) . Ultrasound destruction of microbubbles in the ischemic region releases the genes.
We hypothesize that delivery of VEGF plasmid to the peri-ischemic region of the brain after infarction could be accomplished with UTMD. Ultrasound-targeted microbubble destruction produces a transient disruption in the BBB (12) that is sufficient to permit transfection of cerebral tissue. Therefore, we evaluated VEGF delivery with UTMD for the treatment of ischemic stroke in a murine transient middle cerebral artery occlusion (tMCAO) model. This minimally invasive methodology has significant potential for clinical application.
procedures were carried out according to the National Institutes of Health's ''Guide for the Care and Use of Laboratory Animals,'' which was published in 1996. Ten-to 12-week-old CD1 female mice weighing 22 to 25 g were purchased from Charles River (Wilmington, MA). Animals were anesthesized with a 1.5% isoflurane nose cone. Body temperature was maintained at 37.0-C T 0.5-C.
Ischemic infarcts were induced by tMCAO with an intraluminal filament. Briefly, under an operating microscope, both internal and external carotid arteries were exposed through a neck incision, and a 6-0 rounded Ethilon nylon monofilament (Ethicon, Somerville, NJ) was gently advanced from the external carotid artery to the lumen of the initial segment of the middle cerebral artery for a distance of 10.0 T 0.5 mm.
The monofilament fiber occluded blood flow for 90 minutes, and then the filament was withdrawn to permit reperfusion.
Plasmids and Microbubbles
Three plasmids were used in this study: pcDNA3 carrying the luciferase gene was used in normal mice, whereas pEGFP-N2 carrying the enhanced green fluorescent protein (GFP) gene and pCEP4 carrying the 165-isoform of the human VEGF gene were used in an ischemic brain mice model. All 3 genes were under the control of the cytomegalovirus promoter.
Perflutren lipid microbubbles (Lantheus Medical Imaging, North Billerica, MA) were purchased and prepared as previously described (11) . Microbubbles were allowed to warm to room temperature (RT) and activated for 45 seconds using a Vialmix apparatus (Lantheus Medical Imaging). Then, 25 KL of activated microbubbles was diluted with 25 KL of PBS. Microbubble-plasmid solutions were prepared as previously described, with some modifications (11) . In brief, 20 KL of plasmid DNA (300 Kg/kg body weight) was added to the microbubbles, and the solution was incubated for 10 minutes with gentle agitation.
Application of Transcranial UTMD
Mice were sedated with a 2% isoflurane nose cone. A catheter was placed in the tail vein to deliver the microbubble solution, and the hair over the skull was removed with depilatory lotion. The solution (70 KL) was infused through the catheter for a period of 5 minutes via a microinjection pump, and transcranial UTMD was carried out simultaneously with a diagnostic ultrasound machine (GE Vivid 7; GE Healthcare Canada, Mississauga, Canada), with an M3S transducer operating on second harmonic mode (transmit,1.6 MHz; receive, 3.2 MHz). A mechanical index of 1.3, a power of 0 dB, and a compress of 14 were used. The beam was directed to the left hemisphere of the brain for 5 minutes on intermittent mode (1 burst every 500 milliseconds). The transducer was held in place by a clamp such that it was centered 1 mm posterior to the bregma and 3.0 mm lateral to the midsagittal line.
UTMD-Mediated Delivery of Plasmids
For delivery of the luciferase reporter gene to the normal brain, the mice were randomized to receive either empty vector (control, n = 6) or the luciferase plasmid (n = 8). For delivery of the GFP reporter gene to the ischemic brain, the mice were randomized to receive either empty vector (control) or the GFP plasmid 3 days after tMCAO (n = 4 per group). For delivery of the therapeutic VEGF gene to the ischemic brain, the mice were randomized to 1 of 3 groups: PBS only (control, n = 10), empty vector (n = 10), or VEGF plasmid (n = 9). In each group, a single transcranial UTMD was administered 3 days after tMCAO.
Evaluation of Neurologic Function
Neurologic function in mice was evaluated with the modified neurologic severity score (mNSS), which includes motor, sensory, reflex, and balance tests, as previously described (13) . Neurologic function was graded on a scale from 0 to 18. One point is scored for the inability to perform a test or for lack of a reflex. Therefore, higher scores indicate greater deficiency in neurologic function.
Histologic Analysis
After the evaluation of neurologic function, the mice were killed by anesthetic overdose with 5% isoflurane. Brains were first perfused with ice-cold PBS delivered into the heart and then fixed with 4% paraformaldehyde. The fixed brains were cut into 1-mm-thick coronal sections. The sections were processed, embedded in paraffin, and cut into 5-Km sections for histologic studies. These sections were stained with hematoxylin and eosin.
Assessment of the BBB
To evaluate the effects of UTMD on the disruption of the BBB, we randomly allocated the animals to 1 of 3 groups: PBS only (control), microbubbles delivered once, or microbubbles delivered 3 times (every other day, n = 4 per group). Immediately after the last sonication, the mice received an intravenous injection of 0.06 mL of 4% trypan blue dissolved in PBS. Leakage of trypan blue from the circulation into the brain parenchyma allowed macroscopic visualization of the sonicated areas of the brain after ultrasound-induced disruption of the BBB (14) . After 4 or 24 hours, the animals were killed by anesthetic overdose with 5% isoflurane and underwent transcardiac PBS perfusion. The brains were removed and cut into 1-mm slices. The surface area of the blue-stained cortex was calculated using ImageJ software.
In Vivo Bioluminescence Imaging
At 2, 4, and 7 days after transcranial UTMD delivery of the luciferase plasmid or empty vector, the mice received an intraperitoneal injection of the luciferase reporter substrate D-luciferin (150 mg/kg body weight; Xenogen, Waltham, MA). Metabolically active gene-transfected cells in the brain that express the luciferase enzyme convert luciferin into the inactive photon-producing oxyluciferin. These photons can be captured using a charge-coupled device camera system (IVIS; Xenogen).
GFP and NeuN Immunohistochemistry
Cells expressing GFP and the neuron-specific protein NeuN were identified by immunofluorescent staining of brain tissue 4 days after transcranial UTMD. The mice were killed by anesthetic overdose with 5% isoflurane and underwent transcardiac perfusion with ice-cold PBS, followed by 4% paraformaldehyde. The frozen brain tissue was cut into 5-Km serial coronal sections and incubated with anti-GFP fluorescent antibody (1:400, Alexa Fluor 488; Molecular Probes, Eugene, OR) and anti-NeuN antibody (1:100; Millipore, Billerica, MA) for 1 hour at RT. After wash, the sections were incubated with anti-mouse fluorescent antibody (1:200, Alexa Flour 568; Molecular Probes) for 1 hour at RT. Sections were then stained with 4 ¶,6-diamidino-2-phenylindole (DAPI) (1:1500; Sigma-Aldrich Canada, Oakville, Ontario, Canada) for 5 minutes at RT. Microscope 40Â fields (n = 5) were randomly selected under a Nikon ECLIPSE Ti microscope. The numbers of GFP-positive and NeuN-positive cells per field were manually counted and averaged.
2,3,5-Triphenyltetrazolium Assay of Infarct Area
At 7 days after transcranial UTMD, the mice were killed by anesthetic overdose with 5% isoflurane, and the brains were removed and sliced. Coronal brain slices (1 mm) were incubated in a 1.5% 2,3,5-triphenyltetrazolium solution at 37-C for 15 minutes to differentiate between metabolically active tissue and inactive tissue. 2,3,5-Triphenyltetrazolium in living tissue is enzymatically reduced to a red compound but remains white in inactive tissue. Images were digitalized; infarct areas (PBS and vector control, n = 10 per group, VEGF, n = 9) were calculated using ImageJ software, as previously described (13) .
Reverse TranscriptionYPolymerase Chain Reaction and Western Blot Analysis
Ischemic cerebral hemispheres were snap-frozen on Day 4 after transcranial UTMD-mediated plasmid delivery. Brain homogenates were treated with appropriate extraction buffers, and messenger RNA (mRNA) and protein expressions of VEGF were measured by reverse transcriptionYpolymerase chain reaction (n = 4 per group) and Western blot analysis (PBS and vector control, n = 4 per group; VEGF, n = 6), respectively, as previously described (11) . The detailed procedure was as follows. For reverse transcriptionYpolymerase chain reaction, total RNA was isolated from brain samples using Trizol reagent (Sigma-Aldrich Canada). Reverse transcription was performed using Superscript III (Life Technologies, Carlsbad, CA) at 50-C for 60 minutes. Densitometry of polymerase chain reaction bands was measured using ImageJ software.
The primer sequence for human VEGF (NM_001025366) was follows: human VEGF-F, 5 ¶-aaggaggagggcagaatcat-3 ¶; human VEGF-R, 5 ¶-tttcttgcgctttcgttttt-3 ¶ (polymerase chain reaction, 380 bp). The primers do not amplify the endogenous mouse VEGF (NM_001025250); therefore, the microbubbledelivered exogenous human VEGF gene expression at the mRNA level was strictly distinguishable from endogenous mouse VEGF. Mouse glyceraldehyde-3-phosphate dehydrogenase (GAPDH; NM_008084) housekeeping gene served as a control standard: mouse GAPDH-F, 5 ¶-aactttggcattgtggaagg-3 ¶; mouse GAPDH-R, 5 ¶-ccctgttgctgtagccgtat-3 ¶ (polymerase chain reaction, 472 bp).
For Western blot analysis, each tissue sample was homogenized in lysis buffer (150 mmol/L NaCl, 5 mmol/L EDTA, 10 mmol/L Tris, and 1% Triton X-100 [pH 7.4]). The homogenate was centrifuged at 14,000 Â g at 4-C for 5 minutes. Protein concentration was determined using Bradford protein assay. Equal amounts of protein were subjected to 10% sodium dodecyl sulfateYpolyacrylamide gel electrophoresis and electroblotted onto a nitrocellulose membrane. The membrane was incubated with anti-human VEGF antibody (1:200, SC-507; Santa Cruz Biotechnology, Dallas, TX) at 4-C overnight. After wash, the membrane was incubated with goat anti-rabbit IgG horseradish peroxidase antibody (1:2000; Santa Cruz Biotechnology) for 1 hour. The immunosignal was detected by X-ray film using enhanced chemiluminescence reagents (GE Healthcare). The VEGF level was normalized to the level of GAPDH and expressed as the VEGF-to-GAPDH band intensity ratio.
Quantification of Blood Vessel Density
To quantify vascular density, we prepared 5-Km-thick serial coronal cryosections from brain sections obtained 7 days after UTMD, as described for GFP expression. These sections were stained with antiYfactor VIII antibody (1:200; Dako Canada, Burlington, Canada), followed by anti-rabbit fluorescent antibody (1:200, Alexa Flour 555; Molecular Probes). Vascular density was determined by averaging the number of factor VIIIYpositive blood vessels in 5 randomly selected periinfarct microscopic fields (400Â equals 0.2 mm 2 ) per slide (PBS and vector control, n = 5 per group; VEGF, n = 6).
Quantification of Apoptosis
Terminal dUTP nick-end labeling assay was performed on 5-Km serial coronal cryosections 7 days after UTMD using an in situ Cell Death Detection kit (Roche Diagnostics, Laval, Canada), according to the manufacturer's instructions. Apoptotic cell death was determined by averaging the number of terminal dUTP nick-end labelingYpositive nuclei in 5 randomly selected peri-infarct microscopic fields (400Â equals 0.2 mm 2 ) per slide (n = 3 per group).
Statistical Analysis
Data are expressed as mean T SD. Analyses were performed using GraphPad Prism version 4 (GraphPad, La Jolla, CA). Comparisons between 2 groups were performed with a 2-tailed Student t-test. Multiple group comparisons were performed with 1-way or 2-way analysis of variance. When the F ratio was significant, differences were specified with Tukey or Bonferroni posttests. Differences were considered significant at p G 0.05.
RESULTS

Effects of Transcranial UTMD on Brain Histology and Neurologic Function in Normal Mice
To investigate the safety of transcranial UTMD for gene transfection, we first evaluated the effects of this intervention on normal mouse brains with functional and histologic analyses at 4 hours and 7 days after the last ultrasound exposure. We observed no erythrocyte extravasation into the brain parenchyma of control mice but found a small amount of extravasation in only 1 (14%) of 7 mice treated once with transcranial UTMD (Figs. 1A, B) . Therefore, extravasation was a rare event in 1-time UTMD-mediated gene delivery. Strikingly, at 4 hours after the last ultrasound sonication, a large amount of erythrocyte extravasation was observed in the brain parenchyma of mice treated 3 times with transcranial UTMD (Figs. 1A, C,  arrows) . However, the extravasation was not present at 7 days (Figs. 1B, C) . Thus, 3 applications of UTMD induced only transient extravasation.
The functional results mirrored the histologic observations. The mNSS was increased at 4 hours after the last treatment in mice that received 3 transcranial UTMD treatments, but they returned to normal levels at 7 days (Fig. 1D) . We observed no neurologic functional impairment in control mice or in those treated once with UTMD (Fig. 1D) . These data indicated that 1-time transcranial UTMD did not cause any major adverse effects.
Effects of Transcranial UTMD on the BBB in Normal Mice
To examine if BBB disruption was induced by transcranial UTMD, we injected trypan blue into normal mice after transcranial UTMD. Leakage of the dye from the circulation into the brain parenchyma was detected by macroscopic Reverse transcriptionYpolymerase chain reaction shows that VEGF mRNA levels are significantly elevated in the ischemic cerebral hemisphere of the VEGF group versus the PBS control and empty vector groups at 4 days after UTMD delivery of control vector or VEGF plasmid. (B) Western blot analysis of VEGF protein shows more than 2-fold higher levels in the ischemic cerebral hemisphere of mice receiving the VEGF plasmid compared with those in the control and empty vector groups at 4 days after UTMD. (C) Representative micrographs (400Â) of brain sections obtained 7 days after transcranial UTMD show capillaries in the ischemic region immunolabeled with factor VIII antibody (arrows). Nuclei are stained blue with DAPI. (D) Capillary density was significantly higher in the VEGF plasmid group than in the PBS control and empty vector groups. visualization ( Fig. 2A) . The brains of mice in the PBS control group did not show any blue staining at either 4 or 24 hours after transcranial UTMD ( Fig. 2A) . At 4 hours after the last sonication, the brains of mice that received transcranial UTMD showed obvious blue staining in the sonicated area of the left hemisphere ( Fig. 2A) , and the blue-stained area was significantly greater in the 3-treatment group (16.9 T 4.5 mm 2 ) than in the single-treatment group (10.8 T 2.0 mm 2 ; Fig. 2B ). From 4 to 24 hours, the blue area became smaller in the 3-treatment group (11.3 T 3.6 mm 2 ) and disappeared in the single-treatment group, indicating that the BBB disruption induced by transcranial ultrasound was reversible within 24 hours of a single administration.
Targeted Transcranial UTMD-Mediated Plasmid Delivery to the Normal Brain
Transcranial UTMD was used to deliver the luciferase reporter gene to the brain, and whole-body gene expression was evaluated by in vivo bioluminescence imaging. Control mice received empty vector. All animals that received the luciferase plasmid exhibited a bioluminescent signal at all time points after UTMD. The signal was confined to the sonicated area of the head (Fig. 3A) . Bioluminescence was detected on Day 2, reached the highest level on Day 4, and decreased to its lowest level on Day 7 (Fig. 3B) .
Efficient Transcranial UTMD-Mediated Plasmid Delivery to the Ischemic Brain
The preceding experiment provided proof of concept that a reporter gene could be targeted to the normal brain by transcranial UTMD delivery. Next, we determined whether transcranial UTMD could transfect a reporter gene in a murine ischemic stroke model. Ischemic stroke was induced by tMCAO, and transcranial UTMD was performed 3 days later.
On Day 4 after UTMD delivery of the GFP plasmid, GFP-positive brain cells were detected in the treated region by immunofluorescent staining (Fig. 3C) . The GFP-positive cells were mainly localized to the cortical and superficial subcortical areas in the peri-infarct region, with a few cells scattered in the deeper subcortical area. Double staining with an antibody against NeuN indicated that most of these GFP-positive cells (980%) were not neurons (Figs. 3C, D) . Therefore, a large proportion of transfected cells were glial cells.
VEGF Plasmid Delivery by Transcranial UTMD Increased VEGF Expression and Angiogenesis in the Ischemic Brain
After demonstrating successful reporter gene delivery to the ischemic brain, we investigated whether VEGF overexpression could be achieved with transcranial UTMD gene delivery. To assess transgene expression, we used reverse transcriptionYpolymerase chain reaction to examine human VEGF mRNA expression in the cerebral ischemic region 4 days after plasmid delivery. Levels of VEGF were significantly elevated in the VEGF group compared with the PBS and empty vector control groups (Fig. 4A) . Western blot analysis demonstrated that the level of VEGF protein in the cerebral ischemic region was elevated more than 2-fold in VEGF-treated mice at 7 days after tMCAO (4 days after transcranial UTMD) versus the PBS and empty vector control groups (Fig. 4B) .
To explore the effects of VEGF overexpression on angiogenesis, we evaluated blood vessel density in the periinfarct area by staining for factor VIII (Fig. 4C) . At 7 days after transcranial UTMD, the number of factor VIIIYpositive microvessels in the peri-infarct area of mice that received the VEGF plasmid was 1.6-fold higher than that in mice with infarcts that received PBS or empty vector (Fig. 4D) .
VEGF Plasmid Delivery by Transcranial UTMD Reduced Apoptosis and Infarct Size and Improved Neurologic Function
To investigate whether VEGF overexpression could play a neuroprotective role in ischemic mouse brains, we evaluated neural cell apoptosis by immunofluorescence (Fig. 5A) . At 7 days after transcranial UTMD, the number of terminal dUTP nick-end labelingYpositive apoptotic cells was significantly lower in the VEGF plasmid group than in the PBS and empty vector control groups (Fig. 5A) . Transfection with VEGF reduced apoptosis by 2.5-fold compared with empty vector.
We evaluated the infarct area with 2,3,5-triphenyltetrazolium staining 7 days after transcranial UTMD to differentiate between normal tissue and infarcted tissue. The brains of mice in all groups had clearly visible white infarct areas after tMCAO (Fig. 5B) ; however, as shown in Figure 5C , VEGF treatment significantly decreased the infarct area compared with the PBS and empty vector treatments.
We also evaluated neurologic function for up to 10 days after tMCAO (7 days after UTMD). Data showed that the mNSS increased to a similar degree in all groups 3 days after the ischemic injury (Fig. 5D) , indicating a decline in neurologic function in all mice. The mNSS then decreased in all groups, but the decline (improvement in neurologic function) was significantly greater in the VEGF group than in the PBS and empty vector groups during the 7-day period after transcranial UTMD. Transfection of VEGF plasmid improved neurologic function after a stroke in this mouse model. No differences in the mNSS were found between the PBS group and the empty vector group.
DISCUSSION
This study demonstrates that transcranial UTMD is a safe and effective technique for gene delivery and brain cell transfection after tMCAO in mice. A single transcranial UTMD treatment resulted in a transient increase in BBB permeability, with no lasting adverse histologic or functional effects. Bioluminescence imaging after delivery of the luciferase reporter gene confirmed that gene expression was confined to the targeted region of the brain, and immunostaining for GFP showed that transfected cells were located in the periinfarct region. Other groups have previously demonstrated gene transfection of normal brain tissue mediated by UTMD (15, 16) ; however, we have shown the benefit of this technique in a mouse stroke model. Overexpression of the VEGF gene after transcranial UTMD increased microvessel density, reduced apoptosis, decreased infarct size, and attenuated the impairment of neurologic function in mice with ischemic stroke.
Safety is the most crucial concern for gene therapy in the CNS. Focused ultrasound, alone or combined with microbubbles, has been reported to disrupt the local BBB transiently, thereby increasing regional permeability (12, 15) and facilitating the targeted delivery of therapeutic agents (such as antibodies, drugs, and genes) to the CNS. However, disruption of the BBB must be temporary to avoid local tissue damage, and ultrasound setting must be optimized to prevent prolonged disruption. Erythrocyte extravasation has been reported to be the first indicator of injury after transcranial ultrasound (12) . In our pilot studies, we found that perfusion with PBS or microbubbles alone did not result in extravasation (unpublished data). In the current study, control group animals received saline and ultrasound, which also did not result in extravasation, suggesting that our ultrasound setting alone did not cause extravasation. Therefore, the extravasation observed in the current study was associated with ultrasound destruction of the microbubbles. We found that extravasation was very rare (1 of 7 animals) after 1-time UTMD gene delivery. Because repeated UTMD was reported to prolong the transgene expression of plasmids delivered to the rat heart (17), we examined the feasibility of multiple administrations of transcranial UTMD in normal mice. Our histologic findings demonstrated erythrocyte extravasation as early as 4 hours after the third administration of UTMD, which was associated with decreased neurologic function. However, these adverse effects were resolved by 7 days. Single transcranial UTMD administration did not lead to functional changes but increased BBB permeability 4 hours after treatment. This disruption of the BBB was local and transient, and permeability returned to the normal state within 24 hours. However, after 3 UTMD administrations, BBB permeability did not normalize within 24 hours. Therefore, we chose to use single UTMD administrations in our gene delivery studies.
Ultrasound-targeted microbubble destruction induces different levels of gene expression and attenuation in different organs (7, 11, 17) . In a recent study, peak expression in the brain occurred 2 days after UTMD delivery of an enhanced GFP plasmid (16) . In our study, the duration of gene expression after transcranial UTMD was at least 1 week, with peak expression on Day 4. We anticipate that this brief time for overexpression of angiogenic factors such as VEGF may be optimal because prolonged expression could result in the formation of intramural vascular tumors resembling hemangiomas (18) . In addition, in vivo bioluminescent analysis demonstrated that gene expression was limited to the sonicated area of the head, indicating localized and targeted gene delivery. Transcranial UTMD-mediated gene delivery not only prevented global transgene expression elsewhere in the body but also avoided offtarget expression even within the targeted organ, a distinct advantage over intravenously administered naked plasmids. Of particular interest, targeted delivery avoids the adverse hemodynamic effects that result when VEGF is overexpressed in the whole brain (19) . Using transgenic mice overexpressing human VEGF under a neuron-specific promoter, Wang et al (19) found that, after tMCAO, VEGF overexpression induced the steal phenomenon, with reduced blood flow in the ischemic region and increased blood flow in the remote region.
Brain parenchyma consists mostly of neurons and glial cells. Previous studies demonstrated that both plasmid and viral vectors containing the cytomegalovirus promoter had the tendency to induce greater reporter gene expression in glial cells than in neurons (20, 21) . Yurek et al (21) injected rodlike nanoparticles of compacted plasmid DNA directly into the striatum and reported that more glial cells than neurons were transfected 21 days after injection. Kügler et al (20) reported that adenoviral vectors encoding GFP exhibited stronger expression in astrocytes than in neurons. This is also the case when plasmid is delivered by UTMD. Shimamura et al (7) directly injected luciferase plasmid and microbubbles into the striatum and observed that transfected cells were not neurons; in agreement with other studies, we found that a large proportion of transfected cells were not neurons. Future studies are required to establish which non-neuronal cell types are transfected by UTMD gene delivery to the brain. Because glial cells play an important role in promoting vascular regeneration and neuron survival in cerebral ischemic diseases, upregulating angiogenic or neurotrophic genes in these cells by transcranial UTMD may have therapeutic potential in the treatment of ischemic stroke.
The establishment of new blood vessel networks after acute cerebral infarction is one of the most promising approaches of future therapies in the emerging field of stroke medicine. Angiogenesis is the underlying mechanism for the formation of new blood vessels. Vascular endothelial growth factor is an angiogenic growth factor that is essential for vascular endothelial cell proliferation and survival. In animal stroke models, treatment with VEGF has been demonstrated to induce angiogenesis after intracerebroventricular injection, thereby leading to smaller infarcts and favorable outcomes (4, 9) . In contrast, inhibition of endogenous VEGF decreases angiogenic activity and astrocyte proliferation and results in larger wound cavities in the injured brain (22) . These previous studies, combined with our current data, indicate that VEGF could play an important role in angiogenesis and repair of brain injury after stroke.
Our study does have limitations. First, we did not investigate the effects of stroke on BBB disruption and erythrocyte extravasation. The infarct itself likely induces cerebral BBB disruption and transient hemorrhages, and UTMD might enhance these effects. Future studies need to distinguish the effects of stroke and UTMD on BBB disruption and erythrocyte extravasation. Second, this proof-of-concept study did not identify all of the potential beneficial mechanisms responsible for the functional recovery associated with targeted VEGF gene delivery. For example, we did not examine whether resident or invading cells were transfected by the VEGF vector or whether peri-infarct VEGF overexpression influenced reactive glial cells in the peri-infarct areas. Improved neuronal function may have also resulted not only from enhanced angiogenesis and decreased apoptosis but also from stimulation of endogenous repair mechanisms such as neurogenesis, as suggested by Sun et al (4) . Future studies need to identify the mechanisms associated with beneficial effects and to optimize the delivery of VEGF by UTMD after a stroke.
Transcranial UTMD technology possesses several clinically relevant advantages over other gene delivery techniques that are limited by poor targeting, transfection of healthy tissue, vector immunogenicity, and invasiveness. First, the UTMD technique permits gene delivery by a plasmid and not by a viral vector. Second, the intravenous injection of plasmid avoids the potential complications of intracerebral and intraventricular injections, including infections, bleeding, and injury from needle insertion. Third, the targeted delivery efficiently transfects only the tissue of interest and reduces undesirable gene expression outside the targeted region. Modification of the microbubbles used to carry the therapeutic agent and improved methods for ultrasound targeting may further enhance tissue specificity and increase transfection efficiency. For example, microbubbles can be modified with antibodies to target certain cells, and ultrasound can be carried out under image guidance such as computed tomography or magnetic resonance imaging.
In summary, we found that transcranial UTMD did not induce any lasting adverse effects on brain structure or neurologic function, and that VEGF gene therapy using transcranial UTMD proved beneficial in a murine ischemic stroke model. Therefore, this minimally invasive gene delivery platform has potential in the treatment of stroke and could also be used to deliver drugs such as nitric oxide synthase inhibitors. This transcranial UTMD technique warrants further evaluation, with the hope of improving not only the treatment of stroke but also the treatment of other CNS diseases.
